Search

Your search keyword '"Williams, AnnaLynn"' showing total 250 results
Start Over Author "Williams, AnnaLynn"
250 results on '"Williams, AnnaLynn"'

4. Exercise and epigenetic ages in older adults with myeloid malignancies

Author

Loh, Kah Poh, Sanapala, Chandrika, Jensen-Battaglia, Marielle, Rana, Anish, Sohn, Michael B., Watson, Erin, Gilmore, Nikesha, Klepin, Heidi D., Mendler, Jason H., Liesveld, Jane, Huselton, Eric, LoCastro, Marissa, Susiarjo, Martha, Netherby-Winslow, Colleen, Williams, AnnaLynn M., Mustian, Karen, Vertino, Paula, and Janelsins, Michelle C.

Published
2023
Full Text
View/download PDF

9. Longitudinal patterns of patient-reported cognitive impairment in patients with non-Hodgkin lymphoma (NHL) treated with chemotherapy: A group-based trajectory analysis of a nationwide community-based cohort.

Author

Zhao, Tianming, primary, Janelsins, Michelle Christine, additional, Sun, Hongying, additional, Onitilo, Adedayo A., additional, Curtis, Amarinthia, additional, Misleh, Jamal Ghazi, additional, Culakova, Eva, additional, and Williams, AnnaLynn, additional

Published
2024
Full Text
View/download PDF

10. Supplementary Methods S1 from Systemic Biological Mechanisms of Neurocognitive Dysfunction in Long-Term Survivors of Childhood Hodgkin Lymphoma

Author

Williams, AnnaLynn M., primary, Liu, Wei, primary, Ehrhardt, Matthew J., primary, Mirzaei Salehabadi, Sedigheh, primary, Panoskaltsis-Mortari, Angela, primary, Phillips, Nicholas S., primary, Mulrooney, Daniel A., primary, Flerlage, Jamie E., primary, Yasui, Yutaka, primary, Srivastava, Deokumar, primary, Robison, Leslie L., primary, Hudson, Melissa M., primary, Ness, Kirsten K., primary, Sabin, Noah D., primary, and Krull, Kevin R., primary

Published
2024
Full Text
View/download PDF

11. Supplementary Table S2 from Systemic Biological Mechanisms of Neurocognitive Dysfunction in Long-Term Survivors of Childhood Hodgkin Lymphoma

Author

Williams, AnnaLynn M., primary, Liu, Wei, primary, Ehrhardt, Matthew J., primary, Mirzaei Salehabadi, Sedigheh, primary, Panoskaltsis-Mortari, Angela, primary, Phillips, Nicholas S., primary, Mulrooney, Daniel A., primary, Flerlage, Jamie E., primary, Yasui, Yutaka, primary, Srivastava, Deokumar, primary, Robison, Leslie L., primary, Hudson, Melissa M., primary, Ness, Kirsten K., primary, Sabin, Noah D., primary, and Krull, Kevin R., primary

Published
2024
Full Text
View/download PDF

12. Supplementary Figure S1 from Systemic Biological Mechanisms of Neurocognitive Dysfunction in Long-Term Survivors of Childhood Hodgkin Lymphoma

Author

Williams, AnnaLynn M., primary, Liu, Wei, primary, Ehrhardt, Matthew J., primary, Mirzaei Salehabadi, Sedigheh, primary, Panoskaltsis-Mortari, Angela, primary, Phillips, Nicholas S., primary, Mulrooney, Daniel A., primary, Flerlage, Jamie E., primary, Yasui, Yutaka, primary, Srivastava, Deokumar, primary, Robison, Leslie L., primary, Hudson, Melissa M., primary, Ness, Kirsten K., primary, Sabin, Noah D., primary, and Krull, Kevin R., primary

Published
2024
Full Text
View/download PDF

13. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Author

Roeker, Lindsey, Fox, Christopher, Eyre, Toby, Brander, Danielle, Allan, John, Schuster, Stephen, Nabhan, Chadi, Hill, Brian, Shah, Nirav, Lansigan, Frederick, Yazdy, Maryam, Cheson, Bruce, Lamanna, Nicole, Singavi, Arun, Coombs, Catherine, Barr, Paul, Skarbnik, Alan, Shadman, Mazyar, Ujjani, Chaitra, Tuncer, Hande, Winter, Allison, Rhodes, Joanna, Dorsey, Colleen, Morse, Hannah, Kabel, Charlene, Pagel, John, Williams, Annalynn, Jacobs, Ryan, Goy, Andre, Muralikrishnan, Sivraj, Pearson, Laurie, Sitlinger, Andrea, Bailey, Neil, Schuh, Anna, Kirkwood, Amy, and Mato, Anthony

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Patient Safety, Practice Patterns, Physicians, Proto-Oncogene Proteins c-bcl-2, Retrospective Studies, Sulfonamides, Treatment Outcome, Tumor Lysis Syndrome
Abstract

PURPOSE: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of select adverse events (AE), and impact of dosing modifications in routine clinical practice. EXPERIMENTAL DESIGN: This retrospective cohort study included 297 CLL venetoclax-treated patients outside of clinical trials in academic and community centers. Demographics, baseline disease characteristics, venetoclax dosing, TLS risk and prophylaxis, and AEs were collected. RESULTS: The group was 69% male, 96% had relapsed/refractory CLL, 45% had deletion chromosome 17p, 84% had unmutated IGHV, 80% received venetoclax monotherapy, and median age was 67. TLS risk was categorized as low (40%), intermediate (32%), or high (28%), and 62% had imaging prior to venetoclax initiation. Clinical TLS occurred in 2.7% of patients and laboratory TLS occurred in 5.7%. Pre-venetoclax TLS risk group and creatinine clearance independently predict TLS development in multivariable analysis. Grade 3/4 AEs included neutropenia (39.6%), thrombocytopenia (29.2%), infection (25%), neutropenic fever (7.9%), and diarrhea (6.9%). Twenty-two patients (7.4%) discontinued venetoclax due to an AE. Progression-free survival was similar regardless of number of dose interruptions, length of dose interruption, and stable venetoclax dose. CONCLUSIONS: These data provide insights into current use of venetoclax in clinical practice, including TLS rates observed in clinical practice. We identified opportunities for improved adherence to TLS risk stratification and prophylaxis, which may improve safety.

Published
2019

14. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Author

Mato, Anthony, Roeker, Lindsey, Eyre, Toby, Nabhan, Chadi, Lamanna, Nicole, Hill, Brian, Brander, Danielle, Barr, Paul, Lansigan, Frederick, Cheson, Bruce, Singavi, Arun, Yazdy, Maryam, Shah, Nirav, Allan, John, Bhavsar, Erica, Rhodes, Joanna, Kennard, Kaitlin, Schuster, Stephen, Williams, AnnaLynn, Skarbnik, Alan, Goy, Andre, Goodfriend, Julie, Dorsey, Colleen, Coombs, Catherine, Tuncer, Hande, Ujjani, Chaitra, Jacobs, Ryan, Winter, Allison, Pagel, John, Bailey, Neil, Schuh, Anna, Shadman, Mazyar, Sitlinger, Andrea, Weissbrot, Hanna, Muralikrishnan, Sivraj, Zelenetz, Andrew, Kirkwood, Amy, and Fox, Christopher

Subjects
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Progression-Free Survival, Retrospective Studies, Sulfonamides
Abstract

Venetoclax (VEN) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (VENmono) or in combination with rituximab. Whether VEN plus anti-CD20 (VENcombo) is superior to VENmono is unknown. We conducted a multicenter, retrospective cohort analysis comparing 321 CLL patients treated with VENmono vs VENcombo across the United States and the United Kingdom. We examined demographics, baseline characteristics, dosing, adverse events, response rates, and outcomes. The primary endpoints were progression-free survival (PFS) and overall survival (OS), estimated by Kaplan-Meier method, in patients treated with VENmono vs VENcombo. Univariate and bivariate analyses were performed with COX regression. Three hundred twenty-one CLL patients were included (3 median prior treatments, 78% prior ibrutinib). The overall response rates (ORRs) were similar (VENmono, 81% ORR, 34% complete remission [CR] vs VENcombo, 84% ORR, 32% CR). With a median follow-up of 13.4 months, no differences in PFS and OS were observed between the groups. In unadjusted analyses, the hazard ratios (HRs) for PFS and OS for VENmono vs VENcombo were HR 1.0 (95% confidence interval [CI], 0.6-1.8; P = .7) and HR 1.2 (95% CI, 0.6-2.3; P = .5), respectively. When adjusting for differences between the cohorts, the addition of an anti-CD20 antibody in combination with VEN did not impact PFS (HR, 1.0; 95% CI, 0.5-2.0; P = .9) or OS (HR, 1.1; 95% CI, 0.4-2.6; P = .8). We demonstrate comparable efficacy between VENmono and VENcombo in a heavily pretreated, high-risk, retrospective cohort, in terms of both response data and survival outcomes. Prospective studies are needed to validate these findings.

Published
2019

16. Systemic Biological Mechanisms of Neurocognitive Dysfunction in Long-Term Survivors of Childhood Hodgkin Lymphoma

Author

Williams, AnnaLynn M., primary, Liu, Wei, additional, Ehrhardt, Matthew J., additional, Mirzaei Salehabadi, Sedigheh, additional, Panoskaltsis-Mortari, Angela, additional, Phillips, Nicholas S., additional, Mulrooney, Daniel A., additional, Flerlage, Jamie E., additional, Yasui, Yutaka, additional, Srivastava, Deokumar, additional, Robison, Leslie L., additional, Hudson, Melissa M., additional, Ness, Kirsten K., additional, Sabin, Noah D., additional, and Krull, Kevin R., additional

Published
2024
Full Text
View/download PDF

17. Hypogonadism and neurocognitive outcomes among childhood cancer survivors

Author

Yoshida, Tomoko, primary, Alexander, Tyler, additional, Xing, Mengqi, additional, Mirzaei, Sedigheh, additional, Williams, AnnaLynn M, additional, Lubas, Margaret, additional, Brinkman, Tara M, additional, Chemaitilly, Wassim, additional, Robison, Leslie L, additional, Hudson, Melissa M, additional, Krull, Kevin R, additional, and Delaney, Angela, additional

Published
2024
Full Text
View/download PDF

19. Defining Practice Capacity for Cancer Care Delivery to Adolescents and Young Adults in the Community Setting: 2022 Landscape Assessment Results.

Author

Beauchemin, Melissa P., Ji, Lingyun, Williams, AnnaLynn M., Nightingale, Chandylen L., Dressler, Emily V., Salsman, John M., Santacroce, Sheila J., Freyer, David R., Roth, Michael E., and Parsons, Susan K.

Subjects
COMMUNITY health services, HEALTH services accessibility, CROSS-sectional method, MEDICAL care research, RESEARCH funding, CANCER patient medical care, MEDICAL care, DESCRIPTIVE statistics, HEALTH care teams, COMMUNITY-based social services
Abstract

Background: Adolescents and young adults (AYAs) commonly receive cancer care in the community setting, but the availability of treatment options, resources, and support services for this population is not well known. The National Cancer Institute Community Oncology Research Program (NCORP) funds a network of practices whose mission is to increase access to cancer care and clinical trials in the community setting. We describe our interdisciplinary methodological approach to identify and characterize NCORP practices where AYAs receive cancer care. Methods: NCORP practices completed a cross-sectional Landscape Assessment to describe resources and practice characteristics. We established an interdisciplinary team of stakeholders to analyze the Landscape Assessment data relating to AYAs. Through an iterative process, we assessed NCORP practice responses to questions assessing AYA cancer care capacity, determined a threshold to define practices treating AYAs, and characterized these practices. Results: We determined that practices provide cancer care to AYAs if the following criteria were met: (1) endorsed having an AYA program (n = 20), (2) AYAs comprised ≥5% of annual cancer cases (n = 55), or (3) the practice treated ≥50 AYA cancer cases annually (n = 70). Of 271 NCORP practices, 100 (37%) met any criteria, whereas 87 (32%) did not; 84 (31%) could not be classified due to missing or unknown data. Conclusion: Using an interdisciplinary process, we define practices that treat AYAs in the community. We posit a uniform approach to examine resources and practice capacity for AYAs receiving cancer care across the United States to guide future AYA-focused cancer care delivery research development. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Deficit Accumulation Index and Biological Markers of Aging in Survivors of Childhood Cancer

Author

Williams, AnnaLynn M., primary, Mandelblatt, Jeanne S., additional, Wang, Mingjuan, additional, Dong, Qian, additional, Armstrong, Gregory T., additional, Bhakta, Nickhill, additional, Brinkman, Tara M., additional, Ehrhardt, Matthew J., additional, Mulrooney, Daniel A., additional, Gilmore, Nikesha, additional, Robison, Leslie L., additional, Yasui, Yutaka, additional, Small, Brent J., additional, Srivastava, Deokumar, additional, Hudson, Melissa M., additional, Ness, Kirsten K., additional, Krull, Kevin R., additional, and Wang, Zhaoming, additional

Published
2023
Full Text
View/download PDF

25. Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score

Author

Sesso, Howard D., Beard, Clair J., Curreri, Stephanie, Travis, Lois B., Einhorn, Lawrence H., Brames, Mary Jacqueline, Norton, Kelli, Feldman, Darren R., Oeffinger, Kevin C., Jacobsen, Erin, Silber, Deborah, Hamilton, Rob, Anson-Cartwright, Lynn, Cox, Nancy J., Dolan, M. Eileen, Vaughn, David J., Jacobs, Linda, Panzer, Sarah Lena, Pucci, Donna, Baker, Debbie, Casaceli, Cindy, Fung, Chunkit, Johnson, Eileen, Sahasrabudhe, Deepak, Frisina, Robert D., Bosl, George, Fossa, Sophie D., Gospodarowicz, Mary, Robison, Leslie L., Lipshultz, Steven E., Ardeshir-Rouhani-Fard, Shirin, Monahan, Patrick, Williams, Annalynn M., Hamilton, Robert J., Cook, Ryan, and Zaid, Mohammad Abu

Published
2018
Full Text
View/download PDF

28. Stroke death in patients receiving radiation for head and neck cancer in the modern era

Author

Hardy, Sara J., primary, Bandyopadhyay, Sanjukta, additional, Yang, Hongmei, additional, Williams, Annalynn, additional, Gudina, Abdi, additional, Cummings, Michael A., additional, Zhang, Hong, additional, Singh, Deepinder P., additional, Chen, Yuhchyau, additional, Mohile, Nimish A., additional, Janelsins, Michelle C., additional, and Milano, Michael T., additional

Published
2023
Full Text
View/download PDF

29. Late-onset Cognitive Impairment and Modifiable Risk Factors in Adult Childhood Cancer Survivors

Author

Phillips, Nicholas S., primary, Stratton, Kayla L., additional, Williams, AnnaLynn M., additional, Ahles, Tim, additional, Ness, Kirsten K., additional, Cohen, Harvey Jay, additional, Edelstein, Kim, additional, Yasui, Yutaka, additional, Oeffinger, Kevin, additional, Chow, Eric J., additional, Howell, Rebecca M., additional, Robison, Leslie L., additional, Armstrong, Gregory T., additional, Leisenring, Wendy M., additional, and Krull, Kevin R., additional

Published
2023
Full Text
View/download PDF

30. Epigenetic Age in Peripheral Blood Among Children, Adolescent, and Adult Survivors of Childhood Cancer

Author

Plonski, Noel-Marie, primary, Chen, Cheng, additional, Dong, Qian, additional, Qin, Na, additional, Song, Nan, additional, Parikh, Hemang M., additional, Shelton, Kyla, additional, Finch, Emily R., additional, Easton, John, additional, Mulder, Heather, additional, Zhang, Jinghui, additional, Neale, Geoffrey, additional, Walker, Emily, additional, Wang, Hui, additional, Krull, Kevin, additional, Ness, Kirsten K., additional, Hudson, Melissa M., additional, Robison, Leslie L., additional, Li, Qian, additional, Williams, AnnaLynn, additional, and Wang, Zhaoming, additional

Published
2023
Full Text
View/download PDF

31. Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Author

Roeker, Lindsey E., primary, Fox, Christopher P., primary, Eyre, Toby A., primary, Brander, Danielle M., primary, Allan, John N., primary, Schuster, Stephen J., primary, Nabhan, Chadi, primary, Hill, Brian T., primary, Shah, Nirav N., primary, Lansigan, Frederick, primary, Yazdy, Maryam, primary, Cheson, Bruce D., primary, Lamanna, Nicole, primary, Singavi, Arun K., primary, Coombs, Catherine C., primary, Barr, Paul M., primary, Skarbnik, Alan P., primary, Shadman, Mazyar, primary, Ujjani, Chaitra S., primary, Tuncer, Hande H., primary, Winter, Allison M., primary, Rhodes, Joanna, primary, Dorsey, Colleen, primary, Morse, Hannah, primary, Kabel, Charlene, primary, Pagel, John M., primary, Williams, Annalynn M., primary, Jacobs, Ryan, primary, Goy, Andre, primary, Muralikrishnan, Sivraj, primary, Pearson, Laurie, primary, Sitlinger, Andrea, primary, Bailey, Neil, primary, Schuh, Anna, primary, Kirkwood, Amy A., primary, and Mato, Anthony R., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Author

Roeker, Lindsey E., primary, Fox, Christopher P., primary, Eyre, Toby A., primary, Brander, Danielle M., primary, Allan, John N., primary, Schuster, Stephen J., primary, Nabhan, Chadi, primary, Hill, Brian T., primary, Shah, Nirav N., primary, Lansigan, Frederick, primary, Yazdy, Maryam, primary, Cheson, Bruce D., primary, Lamanna, Nicole, primary, Singavi, Arun K., primary, Coombs, Catherine C., primary, Barr, Paul M., primary, Skarbnik, Alan P., primary, Shadman, Mazyar, primary, Ujjani, Chaitra S., primary, Tuncer, Hande H., primary, Winter, Allison M., primary, Rhodes, Joanna, primary, Dorsey, Colleen, primary, Morse, Hannah, primary, Kabel, Charlene, primary, Pagel, John M., primary, Williams, Annalynn M., primary, Jacobs, Ryan, primary, Goy, Andre, primary, Muralikrishnan, Sivraj, primary, Pearson, Laurie, primary, Sitlinger, Andrea, primary, Bailey, Neil, primary, Schuh, Anna, primary, Kirkwood, Amy A., primary, and Mato, Anthony R., primary

Published
2023
Full Text
View/download PDF

33. Abstract B017: Epigenetic age in peripheral blood among children, adolescent, and adult survivors of childhood cancer

Author

Plonski, Noel-Marie, primary, Chen, Cheng, additional, Dong, Qian, additional, Qin, Na, additional, Shelton, Kyla C., additional, Finch, Emily, additional, Easton, John, additional, Mulder, Heather, additional, Zhang, Jinghui, additional, Neale, Geoffrey, additional, Walker, Emily, additional, Wang, Hui, additional, Krull, Kevin, additional, Ness, Kirsten K., additional, Hudson, Melissa M, additional, Robinson, Leslie L., additional, Li, Qian, additional, Williams, AnnaLynn, additional, and Wang, Zhaoming, additional

Published
2023
Full Text
View/download PDF

34. Abstract A019: Cancer survivor-specific dietary patterns and risk of premature aging in adult survivors of childhood cancer: St. Jude Lifetime (SJLIFE) Cohort

Author

Park, Yikyung, primary, Wang, Mei, additional, Lan, Tuo, additional, Williams, AnnaLynn M., additional, Ehrhardt, Matthew J., additional, Finch, Emily R., additional, Lanctot, Jennifer Q., additional, Jiang, Shu, additional, Krull, Kevin R., additional, Armstrong, Gregory T., additional, Hudson, Melissa M., additional, Colditz, Graham A., additional, Robison, Leslie, additional, and Ness, Kirsten K., additional

Published
2023
Full Text
View/download PDF

35. Abstract B004: Sugar Intake and premature aging in adult survivors of childhood cancer in the St. Jude Lifetime (SJLIFE) Cohort

Author

Lan, Tuo, primary, Wang, Mei, additional, Williams, AnnaLynn M., additional, Ehrhardt, Matthew J., additional, Finch, Emily R., additional, Lanctot, Jennifer Q., additional, Jiang, Shu, additional, Krull, Kevin R., additional, Armstrong, Gregory T., additional, Hudson, Melissa M., additional, Colditz, Graham A., additional, Robison, Leslie, additional, Ness, Kirsten K., additional, and Park, Yikyung, additional

Published
2023
Full Text
View/download PDF

36. Abstract PR014: Sugar Intake and premature aging in adult survivors of childhood cancer in the St. Jude Lifetime (SJLIFE) Cohort

Author

Lan, Tuo, primary, Wang, Mei, additional, Williams, AnnaLynn M., additional, Ehrhardt, Matthew J., additional, Finch, Emily R., additional, Lanctot, Jennifer Q., additional, Jiang, Shu, additional, Krull, Kevin R., additional, Armstrong, Gregory T., additional, Hudson, Melissa M., additional, Colditz, Graham A., additional, Robison, Leslie, additional, Ness, Kirsten K., additional, and Park, Yikyung, additional

Published
2023
Full Text
View/download PDF

39. Epigenetic Age Acceleration and Neurocognitive Function Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort

Author

Williams, AnnaLynn M, primary, Dong, Qian, additional, Phillips, Nicholas S., additional, Ehrhardt, Matt J., additional, Srivastava, Deokumar, additional, Mirzaei Salehabadi, Sedigheh, additional, Yasui, Yutaka, additional, Ness, Kirsten K., additional, Hudson, Melissa M., additional, Robison, Leslie L., additional, Krull, Kevin R., additional, and Wang, Zhaoming, additional

Published
2022
Full Text
View/download PDF

40. Premature aging as an accumulation of deficits in young adult survivors of pediatric cancer

Author

Williams, AnnaLynn M, primary, Mandelblatt, Jeanne, additional, Wang, Mingjuan, additional, Armstrong, Gregory T, additional, Bhakta, Nickhill, additional, Brinkman, Tara M, additional, Chemaitilly, Wassim, additional, Ehrhardt, Matthew J, additional, Mulrooney, Daniel A, additional, Small, Brent J, additional, Wang, Zhaoming, additional, Srivastava, Deokumar, additional, Robison, Leslie L, additional, Hudson, Melissa M, additional, Ness, Kirsten K, additional, and Krull, Kevin R, additional

Published
2022
Full Text
View/download PDF

42. Protein, fat, and animal food intakes and premature aging in adult survivors of childhood cancer: St. Jude Lifetime (SJLIFE) cohort.

Author

Park, Yikyung, primary, Williams, AnnaLynn, additional, Finch, Emily R, additional, Lanctot, Jennifer Q., additional, Jiang, Shu, additional, Krull, Kevin R., additional, Armstrong, Gregory T., additional, Hudson, Melissa M., additional, Colditz, Graham A., additional, Robison, Leslie L., additional, and Ness, Kirsten K., additional

Published
2022
Full Text
View/download PDF

43. Longitudinal associations between psychosocial morbidity, chronic health conditions, quality of life, and mortality in adult survivors of childhood cancer.

Author

Lubas, Margaret, primary, Liu, Wei, additional, Papini, Chiara, additional, Webster, Rachel Tillery, additional, Willard, Victoria W, additional, Ehrhardt, Matthew J., additional, Williams, AnnaLynn, additional, Huang, I-Chan, additional, Srivastava, Deokumar, additional, Armstrong, Gregory T., additional, Krull, Kevin R., additional, Robison, Leslie L., additional, Ness, Kirsten K., additional, Hudson, Melissa M., additional, and Brinkman, Tara M., additional

Published
2022
Full Text
View/download PDF

44. Neuropathy and neurocognitive impairment in long-term survivors of pediatric cancer treated without central nervous system (CNS) directed therapy.

Author

Williams, AnnaLynn, primary, Phillips, Nicholas Steve, additional, Goodenough, Chelsea Goodliffe, additional, Brinkman, Tara M., additional, Papini, Chiara, additional, Jacola, Lisa M, additional, Delaney, Angela M., additional, Armstrong, Gregory T., additional, Jefferies, John L., additional, Khan, Raja B., additional, Robison, Leslie L., additional, Hudson, Melissa M., additional, Ness, Kirsten K., additional, and Krull, Kevin R., additional

Published
2022
Full Text
View/download PDF

46. Premature Aging as an Accumulation of Deficits in Young Adult Survivors of Pediatric Cancer.

Author

Williams, AnnaLynn M, Mandelblatt, Jeanne, Wang, Mingjuan, Armstrong, Gregory T, Bhakta, Nickhill, Brinkman, Tara M, Chemaitilly, Wassim, Ehrhardt, Matthew J, Mulrooney, Daniel A, Small, Brent J, Wang, Zhaoming, Srivastava, Deokumar, Robison, Leslie L, Hudson, Melissa M, Ness, Kirsten K, and Krull, Kevin R

Subjects
*PREMATURE aging (Medicine), *CHILDHOOD cancer, *YOUNG adults, *CANCER survivors, *RACE, *CANCER fatigue
Abstract

Background: We aimed to characterize premature aging as an accumulation of deficits in survivors of pediatric cancer compared to community controls and examine associations with host/treatment factors, neurocognition, and mortality.Methods: Pediatric cancer survivors (N = 4,000, median age 28.6 [IQR 23-35], 20 [15-27] years post-diagnosis) and community controls (N = 638, median age 32 [25-40]) completed clinical assessments, questionnaires, and were followed for mortality through April 30th, 2020 (mean [SD] follow-up 7.0 [3.4] years). A deficit accumulation index (DAI) score was calculated from 44 aging-related items including: self-reported daily function, psychosocial symptoms, and health conditions. Items were weighted from 0 (absent) to 1 (present/most severe), summed and divided by the total yielding a ratio (higher=more deficits). Scores <0.20 are robust and 0.06 is a clinically meaningful difference. Linear regression compared the DAI in survivors and controls with an age*survivor/control interaction. Logistic regression and Cox-proportional hazards estimated the risk of neurocognitive impairment and death. Models were minimally adjusted for age, sex, and race andethnicity.Results: The adjusted mean DAI among survivors at age 30 years was 0.16 corresponding to age 63 in controls (33 years premature aging; β = 0.07 95%CI 0.06-0.08; p<.001). Cranial/abdominal radiation, alkylators, platinum, and neurosurgery were associated with worse DAI (p's≤.001). Higher scores were associated with increased risk of neurocognitive impairment in all domains (p's<.001) and increased risk of death (DAI 0.20-0.35 HR = 2.80, 95%CI 1.97-3.98; DAI ≥0.35 HR = 5.08, 95%CI 3.52-7.34).Conclusion:  Pediatric cancer survivors experience significant premature aging. The DAI may be used to identify survivors at greatest risk of poor health outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Physiologic Frailty and Neurocognitive Decline Among Young-Adult Childhood Cancer Survivors: A Prospective Study From the St Jude Lifetime Cohort

Author

Williams, AnnaLynn M., primary, Krull, Kevin R., additional, Howell, Carrie R., additional, Banerjee, Pia, additional, Brinkman, Tara M., additional, Kaste, Sue C., additional, Partin, Robyn E., additional, Srivastava, Deokumar, additional, Yasui, Yutaka, additional, Armstrong, Gregory T., additional, Robison, Leslie L., additional, Hudson, Melissa M., additional, and Ness, Kirsten K., additional

Published
2021
Full Text
View/download PDF

49. Accelerated cognitive decline in adult survivors of pediatric central nervous system (CNS) tumors: A report from the Childhood Cancer Survivor Study (CCSS).

Author

Phillips, Nicholas Steve, primary, Stratton, Kayla, additional, Williams, AnnaLynn M., additional, Liu, Wei, additional, Ahles, Tim, additional, Ness, Kirsten K., additional, Gibson, Todd M., additional, Banerjee, Pia, additional, Yasui, Yutaka, additional, Oeffinger, Kevin C., additional, Chow, Eric Jessen, additional, Howell, Rebecca M., additional, Robison, Leslie L., additional, Armstrong, Gregory T., additional, Leisenring, Wendy M., additional, and Krull, Kevin R., additional

Published
2021
Full Text
View/download PDF

50. Effects of metabolic syndrome on cognitive outcomes in long-term survivors of childhood cancer.

Author

Alexander, Tyler, primary, Liu, Wei, additional, Dixon, Stephanie B, additional, Williams, AnnaLynn M., additional, Chemaitilly, Wassim, additional, Mulrooney, Daniel A., additional, Ness, Kirsten K., additional, Brinkman, Tara M., additional, Banerjee, Pia, additional, Srivastava, Deokumar, additional, Robison, Leslie L., additional, Hudson, Melissa M., additional, and Krull, Kevin R., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results